The short version
6 companies supply this market — a reasonable cushion if one runs into trouble.
Market view
pimavanserin tartrate · Powder
6 marketed package NDCs · 6 active manufacturers
Most dispensed: 34 mg · Capsule · #30 capsules/bottle, plastic
Same drug class
Other molecules FDA puts in Atypical Antipsychotic, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- olanzapine and fuoxetine· 1 maker
- olanzapine and samidorphan l-malate· 1 maker
- aripiprazole orally disintegrating· 2 makers
- lumateperone· 2 makers
- olanzapine and fluoxetine· 2 makers
- quetiapine fumarate er· 2 makers
- aripiprazole oral· 3 makers
- cariprazine· 3 makers
- lurasidone hcl· 3 makers
- asenapine· 4 makers
- aripiprazole lauroxil· 6 makers
- ziprasidone hcl· 6 makers
Common questions
- Is Pimavanserin tartrate in shortage right now?
- No. FDA does not currently list Pimavanserin tartrate in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Pimavanserin tartrate?
- 9 companies have marketed Pimavanserin tartrate in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Pimavanserin tartrate cost?
- The typical pharmacy pays about $170.50 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.